Traders should monitor upcoming regulatory milestones in China and potential data presentations in 2026, which could further de-risk the asset. Approval could significantly boost GSK's growth profile and valuation, particularly in the infectious disease segment.
Price Chart
Executive Summary
GSK announced that the China National Medical Products Administration (NMPA) has accepted for review its new drug application for bepirovirsen, an investigational antisense oligonucleotide for a potential functional cure for chronic hepatitis B. The submission is supported by positive Phase III B-Well trial results showing statistically significant and clinically meaningful functional cure rates, with the drug already holding Breakthrough Therapy designation in China. If approved, bepirovirsen could address a major unmet medical need affecting an estimated 75 million people in China.
Key Facts
- NMPA in China has accepted the NDA for bepirovirsen for review as a potential first-in-class functional cure for chronic hepatitis B (CHB).
- The submission is backed by statistically significant and clinically meaningful functional cure rates from pivotal Phase III B-Well 1 and B-Well 2 trials.
- Bepirovirsen received Breakthrough Therapy designation in China in August 2021, expediting its regulatory review.
- An estimated 75 million people in China live with CHB, with ~450,000 deaths annually; current standard of care has only ~1% functional cure rate.
- Bepirovirsen is an investigational antisense oligonucleotide licensed from Ionis Pharmaceuticals and is not yet approved anywhere globally.
Financial Impact
High commercial potential in China and globally if approved; could generate billions in peak sales given the large patient population and lack of effective cures.
Risk Factors
- Regulatory approval is not guaranteed despite Breakthrough Therapy designation.
- Safety or efficacy concerns could emerge in future data disclosures or regulatory reviews.
- Commercial uptake may be limited by pricing, reimbursement, or competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-002919 |
| Document: 0001654954-26-002919-index-headers.html | 0001654954-26-002919 |
| Document: 0001654954-26-002919-index.html | 0001654954-26-002919 |
| Document: 0001654954-26-002919.txt | 0001654954-26-002919 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers